Kristian Reich's most recent trade in MoonLake Immunotherapeutics - Ordinary Shares - Class A was a trade of 520,342 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 7, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| MoonLake Immunotherapeutics (Class A) | Kristian Reich | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2026 | 520,342 | 520,342 | - | - | Stock Option (Right to Buy) | |
| MoonLake Immunotherapeutics (Class A) | Kristian Reich | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 Dec 2025 | 35,389 | 0 | - | - | Class C ordinary shares, par value $0.0001 per share | |
| MoonLake Immunotherapeutics (Class A) | Kristian Reich | Chief Scientific Officer | 19 Dec 2025 | 35,389 | 35,389 | - | - | Class A ordinary shares, par value $0.0001 per share | ||
| MoonLake Immunotherapeutics (Class A) | Kristian Reich | Chief Scientific Officer | 19 Dec 2025 | 1,052 | 0 | - | - | Common shares, par value CHF 0.10 per share, of MoonLake AG | ||
| MoonLake Immunotherapeutics (Class A) | Kristian Reich | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 15.08 per share. | 08 Dec 2025 | 130,000 | 72,908 | - | 15.1 | 1,960,400 | Class A ordinary shares, par value $0.0001 per share |
| MoonLake Immunotherapeutics (Class A) | Kristian Reich | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 14.43 per share. | 08 Dec 2025 | 72,908 | 0 | - | 14.4 | 1,052,062 | Class A ordinary shares, par value $0.0001 per share |
| MoonLake Immunotherapeutics (Class A) | Kristian Reich | Chief Scientific Officer | 02 Sep 2025 | 48,978 | 202,908 | - | - | Class A ordinary shares, par value $0.0001 per share | ||
| MoonLake Immunotherapeutics (Class A) | Kristian Reich | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Sep 2025 | 48,978 | 35,389 | - | - | Class C ordinary shares, par value $0.0001 per share | |
| MoonLake Immunotherapeutics (Class A) | Kristian Reich | Chief Scientific Officer | 02 Sep 2025 | 1,456 | 1,052 | - | - | Common shares, par value CHF 0.10 per share, of MoonLake AG | ||
| MoonLake Immunotherapeutics (Class A) | Kristian Reich | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 139,273 | 139,273 | - | - | Stock Option (Right to Buy) | |
| MoonLake Immunotherapeutics (Class A) | Kristian Reich | Chief Scientific Officer | 20 Jan 2025 | 111,949 | 153,930 | - | - | Class A ordinary shares, par value $0.0001 per share | ||
| MoonLake Immunotherapeutics (Class A) | Kristian Reich | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 Jan 2025 | 111,949 | 84,367 | - | - | Class C ordinary shares, par value $0.0001 per share | |
| MoonLake Immunotherapeutics (Class A) | Kristian Reich | Chief Scientific Officer | 20 Jan 2025 | 3,328 | 2,508 | - | - | Common shares, par value CHF 0.10 per share, of MoonLake AG | ||
| MoonLake Immunotherapeutics (Class A) | Kristian Reich | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 55.00 per share. | 27 Feb 2024 | 31,910 | 2,925,573 | - | 55 | 1,755,050 | Class A ordinary shares, par value $0.0001 per share |
| MoonLake Immunotherapeutics (Class A) | Reich Kristian | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 55.00 per share. | 27 Feb 2024 | 29,491 | 2,957,483 | - | 55 | 1,622,005 | Class A ordinary shares, par value $0.0001 per share |
| MoonLake Immunotherapeutics (Class A) | Kristian Reich | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 55.00 per share. | 27 Feb 2024 | 29,431 | 70,071 | - | 55 | 1,618,705 | Class A ordinary shares, par value $0.0001 per share |
| MoonLake Immunotherapeutics (Class A) | Kristian Reich | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 55.00 per share. | 27 Feb 2024 | 28,090 | 41,981 | - | 55 | 1,544,950 | Class A ordinary shares, par value $0.0001 per share |
| MoonLake Immunotherapeutics (Class A) | Kristian Reich | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 57.43 per share. | 20 Feb 2024 | 10,000 | 100,071 | - | 57.4 | 574,300 | Class A ordinary shares, par value $0.0001 per share |
| MoonLake Immunotherapeutics (Class A) | Reich Kristian | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 57.45 per share. | 20 Feb 2024 | 10,000 | 2,987,483 | - | 57.5 | 574,500 | Class A ordinary shares, par value $0.0001 per share |
| MoonLake Immunotherapeutics (Class A) | Kristian Reich | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 55.30 per share. | 20 Feb 2024 | 569 | 99,502 | - | 55.3 | 31,466 | Class A ordinary shares, par value $0.0001 per share |
| MoonLake Immunotherapeutics (Class A) | Reich Kristian | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 55.31 per share. | 20 Feb 2024 | 509 | 2,986,974 | - | 55.3 | 28,153 | Class A ordinary shares, par value $0.0001 per share |
| MoonLake Immunotherapeutics (Class A) | Kristian Reich | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 60.16 per share. | 14 Feb 2024 | 10,000 | 120,071 | - | 60.2 | 601,600 | Class A ordinary shares, par value $0.0001 per share |
| MoonLake Immunotherapeutics (Class A) | Reich Kristian | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 62.43 per share. | 14 Feb 2024 | 10,000 | 130,071 | - | 62.4 | 624,300 | Class A ordinary shares, par value $0.0001 per share |
| MoonLake Immunotherapeutics (Class A) | Kristian Reich | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 60.15 per share. | 14 Feb 2024 | 10,000 | 110,071 | - | 60.2 | 601,500 | Class A ordinary shares, par value $0.0001 per share |
| MoonLake Immunotherapeutics (Class A) | Reich Kristian | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 60.15 per share. | 14 Feb 2024 | 10,000 | 2,997,483 | - | 60.2 | 601,500 | Class A ordinary shares, par value $0.0001 per share |
| MoonLake Immunotherapeutics (Class A) | Reich Kristian | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 60.17 per share. | 14 Feb 2024 | 10,000 | 3,007,483 | - | 60.2 | 601,700 | Class A ordinary shares, par value $0.0001 per share |
| MoonLake Immunotherapeutics (Class A) | Kristian Reich | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 62.42 per share. | 14 Feb 2024 | 10,000 | 3,017,483 | - | 62.4 | 624,200 | Class A ordinary shares, par value $0.0001 per share |
| MoonLake Immunotherapeutics (Class A) | Kristian Reich | Chief Scientific Officer | 05 Apr 2023 | 500,006 | 500,006 | - | - | Class A ordinary shares, par value $0.0001 per share | ||
| MoonLake Immunotherapeutics (Class A) | Kristian Reich | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2023 | 500,006 | 2,527,477 | - | - | Class C ordinary shares, par value $0.0001 per share | |
| MoonLake Immunotherapeutics (Class A) | Kristian Reich | Chief Scientific Officer | 05 Apr 2023 | 98,090 | 98,090 | - | - | Class A ordinary shares, par value $0.0001 per share | ||
| MoonLake Immunotherapeutics (Class A) | Kristian Reich | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2023 | 98,090 | 238,297 | - | - | Class C ordinary shares, par value $0.0001 per share | |
| MoonLake Immunotherapeutics (Class A) | Kristian Reich | Chief Scientific Officer | 05 Apr 2023 | 14,864 | 75,136 | - | - | Common shares, par value CHF 0.10 per share, of MoonLake AG | ||
| MoonLake Immunotherapeutics (Class A) | Kristian Reich | Chief Scientific Officer | 05 Apr 2023 | 2,916 | 7,084 | - | - | Common shares, par value CHF 0.10 per share, of MoonLake AG |